Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
Targeting CXCR4 during PET scans could help providers gain vital information regarding patients' potential to fully recover from myocardial infarction.
Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.
PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.
GLP-1 receptor agonists alter glucose metabolism and the movement of food through the digestive system and can lead to unique uptake patterns on FDG PET-CT.
A comparison of the detection rates for 68Ga-PSMA PET/CT and mpMRI in low, intermediate and high-risk prostate cancer was recently shared by experts in EJNMMI.
Such scans determined the final diagnosis in 54% of patients and were more accurate than CRP and WBC levels for identifying fever origin, according to research published in Scientific Reports.
"The accuracy of PSMA-PET is essential to improve stratification and potentially outcomes both in low-risk and high-risk settings,” a doctor involved in the study explained in the Journal of Nuclear Medicine.
“We showed that risk prediction does not depend on cardiovascular risk scores, stenosis severity or CT calcium scoring," researchers said in the Journal of Nuclear Medicine.